← Eichor
Condition: Fgfr2 Gene Fusion Rearrangement Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Fgfr2 Gene Fusion Rearrangement

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients
Phase 2 · 2 location(s) · Mehmet Akce · NCT06728410Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
Phase 2 · 65 location(s) · Taiho Oncology, Inc. · NCT05727176Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations
Phase 1 · 4 location(s) · Tyra Biosciences, Inc · NCT06160752HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma
Phase 2/Phase 3 · 1 location(s) · Hutchmed · NCT04353375A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement
Phase 2 · 19 location(s) · Elevar Therapeutics · NCT07359820
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.